Skip to main content

Lexeo Therapeutics, Inc.

LXEO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001907108

In the last 90 days, Lexeo Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 141 institutions reported holding it in 13F filings for Q2 2026, worth $410.9M in total; no superinvestor holds it.

Holders of 5% or more of LXEO

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Lexeo Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of LXEO
HolderLatest formStakeChangeFirst filedLatest filingFiling
Janus Henderson Group PLC13G/A9.99%7.29M shares−1.31 ppfrom 11.30%Feb 14, 20255 filingsDec 8, 2025SEC
Balyasny Asset Management LLC13G/A9.99%5.39M shares0.00 ppfrom 9.99%Aug 14, 20252 filingsNov 14, 2025SEC
Citadel Advisors LLC13G/A9.60%5.33M shares–Aug 14, 20251 filingAug 14, 2025SEC
Affinity Asset Advisors, LLC13G7.75%4.25M sharesNewJun 4, 20251 filingJun 4, 2025SEC
Vestal Point Capital, LP13G/A7.50%4.12M shares+1.50 ppfrom 6.00%Aug 14, 20252 filingsNov 14, 2025SEC
Ra Capital Management, L.P.13G6.90%5.00M sharesNewOct 27, 20251 filingOct 27, 2025SEC
Mizuho Financial Group Inc13G/A6.60%2.20M shares+0.80 ppfrom 5.80%Feb 13, 20252 filingsMay 13, 2025SEC
Frazier Life Sciences Public Fund, L.P.13G/A5.70%3.07M shares−4.20 ppfrom 9.90%Jun 4, 20252 filingsAug 14, 2025SEC
Paradigm Biocapital Advisors LP13G5.00%3.67M sharesNewNov 20, 20251 filingNov 20, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

29 Schedule 13D and 13G filings on Lexeo Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on LXEO
Filed (ET)FilerFormStakeChangeEvent dateFiling
Mar 27, 202610:16 AM ETVanguard Group Inc13G/A0.00%0 shares–Below 5%Mar 13, 2026SEC
Dec 8, 202511:45 AM ETJanus Henderson Group PLC13G/A9.99%7.29M shares−1.31 ppfrom 11.30%Nov 28, 2025SEC
Nov 20, 20254:30 PM ETParadigm Biocapital Advisors LPand 3 others13G5.00%3.67M sharesNewNov 13, 2025SEC
Nov 14, 20254:17 PM ETLongitude Capital Partners IV, LLCand 3 others13G/A3.80%2.77M shares–Below 5%Sep 30, 2025SEC
Nov 14, 20254:00 PM ETVestal Point Capital, LPand 1 other13G/A7.50%4.12M shares+1.50 ppfrom 6.00%Sep 30, 2025SEC
Nov 14, 202512:49 PM ETJanus Henderson Group PLCand 1 other13G/A11.30%6.11M shares+0.20 ppfrom 11.10%Sep 30, 2025SEC
Nov 14, 20256:04 AM ETBalyasny Asset Management LLCand 4 others13G/A9.99%5.39M shares0.00 ppfrom 9.99%Sep 30, 2025SEC
Nov 7, 20254:42 PM ETIntegrated Core Strategies (US) LLCand 3 others13G/A3.20%2.31M shares−2.10 ppfrom 5.30%Below 5%Sep 30, 2025SEC
Oct 27, 20254:07 PM ETRa Capital Management, L.P.and 3 others13G6.90%5.00M sharesNewOct 20, 2025SEC
Oct 17, 20256:13 PM ETBlackRock, Inc.13G/A4.00%2.17M shares−1.50 ppfrom 5.50%Below 5%Sep 30, 2025SEC
Aug 14, 20254:58 PM ETCitadel Advisors LLCand 6 others13G/A9.60%5.33M shares–Jun 30, 2025SEC
Aug 14, 20253:51 PM ETVestal Point Capital, LPand 1 other13G6.00%3.23M sharesNewJun 30, 2025SEC
Aug 14, 20251:40 PM ETFrazier Life Sciences Public Fund, L.P.and 19 others13G/A5.70%3.07M shares−4.20 ppfrom 9.90%Jun 30, 2025SEC
Aug 14, 202511:46 AM ETJanus Henderson Group PLCand 1 other13G/A11.10%3.68M shares−2.60 ppfrom 13.70%Jun 30, 2025SEC
Aug 14, 20256:40 AM ETBalyasny Asset Management LLCand 4 others13G9.99%8.35M sharesNewJun 30, 2025SEC
Aug 7, 20254:18 PM ETIntegrated Core Strategies (US) LLCand 3 others13G/A5.30%2.84M shares−0.50 ppfrom 5.80%Jun 30, 2025SEC
Jun 4, 20254:51 PM ETFrazier Life Sciences Public Fund, L.P.and 19 others13G9.90%5.50M sharesNewMay 28, 2025SEC
Jun 4, 20254:04 PM ETAffinity Asset Advisors, LLCand 1 other13G7.75%4.25M sharesNewMay 28, 2025SEC
May 15, 20259:58 AM ETD1 Capital Partners L.P.and 1 otherSuperinvestorD1 Capital Partners13G/A2.90%978.7K shares–Below 5%Mar 31, 2025SEC
May 14, 202512:00 PM ETJanus Henderson Group PLCand 1 other13G/A13.70%4.56M shares+0.60 ppfrom 13.10%Mar 31, 2025SEC
May 13, 20256:55 AM ETMizuho Financial Group Inc13G/A6.60%2.20M shares+0.80 ppfrom 5.80%Mar 31, 2025SEC
May 12, 20259:00 AM ETAdage Capital Management, L.P.and 2 others13G/A0.70%238.0K shares−5.98 ppfrom 6.68%Below 5%Mar 31, 2025SEC
Apr 28, 20254:03 PM ETIntegrated Core Strategies (US) LLCand 3 others13G5.80%1.93M sharesNewApr 22, 2025SEC
Feb 14, 202512:03 PM ETEventide Asset Management, LLCand 2 others13G/A3.73%1.23M shares–Below 5%Dec 31, 2024SEC
Feb 14, 202511:55 AM ETJanus Henderson Group PLCand 1 other13G/A13.10%4.34M shares–Dec 31, 2024SEC
Feb 14, 20259:00 AM ETOmega Fund VI, L.P.and 5 others13G/A3.60%1.18M shares–Below 5%Dec 31, 2024SEC
Feb 13, 202510:24 AM ETMizuho Financial Group Inc13G5.80%1.93M sharesNewDec 31, 2024SEC
Feb 12, 20259:35 AM ETAdage Capital Management, L.P.and 2 others13G/A6.68%2.21M shares–Dec 31, 2024SEC
Feb 4, 20253:45 PM ETBlackRock, Inc.13G5.50%1.82M sharesNewDec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Lexeo Therapeutics, Inc. shares.

No Form 144 notices for Lexeo Therapeutics, Inc. are on file.